Close Bookmark and Share This Page

Save to Browser Favorites / Bookmarks

Ask backflip blinklist BlogBookmark Bloglines BlogMarks Blogsvine BuddyMarks BUMPzee! CiteULike Connotea del.icio.us

Digg diigo DotNetKicks DropJack dzone Facebook Fark Faves Friendsite folkd.com Furl Google

Jamespot Jeqq Kaboodle kirtsy linkaGoGo LinkedIn Ma.gnolia Mister Wong Mixx MySpace Netvouz Newsvine

oneview OnlyWire PlugIM Propeller Reddit Segnalo Shoutwire Simpy Slashdot Surphace Sphinn Spurl

Squidoo StumbleUpon Technorati ThisNext Twitter Webride Windows Live Yahoo!

Email This to a Friend

  Link HTML: 

 Permalink: 

 If you like this then please subscribe to the RSS Feed.

Powered by Bookmarkify™

More »

Drugmaker Valeant Pharmaceuticals International Inc. (TSX:VRX) said Monday it approved an increase of $300 million in its program to repurchase shares, senior notes and other securities.

The Mississauga, Ont.-based company said it the addition increases its buyback authority to up to $1.8 billion.

Valeant said that under that authorization, it has bought back 15 million shares for $509.6 million, and $302.5 million in convertible notes for $806.3 million. The repurchase authorization is scheduled to expire Nov. 7.

Valeant plans to buy back up to 16 million shares, or about 10 per cent of its total share count. Earlier this month, the company filed notice that it planned to buy back 1 million of its shares on the Toronto Stock Exchange.

It plans to buy back the other 15 million shares through the New York Stock Exchange.

Regards,

Don